Changing the Practice of Medicine
Popular
- CME/CE
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
1.00 credit
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
- CME/CE In-Person & Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 11, 2026
Houston, Texas Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Chan Y. Cheah, MBBS
Alessandra Tedeschi, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
CME/CE
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Aditya Bardia, MD, MPH, FASCO
Clinical Practice
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Erica L. Mayer, MD, MPH
- CME/CE Broadcast Replay
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
1.00 creditMaria Fleseriu, MD, FACE
Shlomo Melmed, MBChB
Elise M. Brett, MD, FACE
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Programs
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Michael Dolinger, MD, MBA
David T. Rubin, MD
Michael Dolinger, MD, MBA
David T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD